«These results indicate that
tamoxifen is a pharmacologically attractive scaffold for the development of new anti-cryptococcal drugs and
provide a mechanistic base for its further optimization.»
The 2nd session
provided an overview of cases, as evidence for clinical use of pharmacogenomics, focusing onTPMT genotyping for thiopurine treatment (Dr. Marieke Coenen, Radboud University, Nijmegen, the Netherlands), DPYD genotyping (Dr. Linda Henricks, Netherlands Cancer Institute (NKI), Amsterdam, the Netherlands),
tamoxifen and CYP2D6 genotyping (Prof. Matthias Schwabb, Margarete Fisher Bosch Institute, Stuttgart, Germany) and SLCO1B1 and statin pharmacogenomics (Prof. Mikko Niemi, University of Helsinki, Helsinki, Finland).